2023
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer
Mayer E, Tayob N, Ren S, Savoie J, Spigel D, Burris H, Ryan P, Harris L, Winer E, Burstein H. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Research And Treatment 2023, 204: 123-132. PMID: 38019444, DOI: 10.1007/s10549-023-07167-9.Peer-Reviewed Original ResearchObjective response rateProgression-free survivalAdvanced breast cancerPhase II studyMetastatic breast cancerOverall survivalArm ABreast cancerArm BII studyMetronomic chemotherapyRandomized phase II studyGrade adverse eventsMetronomic oral cyclophosphamideOral metronomic chemotherapyMedian overall survivalStandard-dose chemotherapyFurther clinical evaluationMetronomic cyclophosphamideOral cyclophosphamideArm B.Primary endpointSecondary endpointsAdverse eventsDose chemotherapyCombined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian J, Chen J, Chao S, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen J, Abrams T, Clark J, Enzinger A, Enzinger P, Klempner S, McCleary N, Meyerhardt J, Ryan D, Yurgelun M, Kanter K, Van Seventer E, Baiev I, Chi G, Jarnagin J, Bradford W, Wong E, Michel A, Fetter I, Siravegna G, Gemma A, Sharpe A, Demehri S, Leary R, Campbell C, Yilmaz O, Getz G, Parikh A, Hacohen N, Corcoran R. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nature Medicine 2023, 29: 458-466. PMID: 36702949, PMCID: PMC9941044, DOI: 10.1038/s41591-022-02181-8.Peer-Reviewed Original ResearchConceptsPrimary end pointColorectal cancerResponse rateEnd pointPD-1Immune responseSingle-arm phase 2 clinical trialMAPK inhibitionMEK inhibitionPhase 2 clinical trialTreatment tumor biopsiesDisease control rateSecondary end pointsPhase 2 trialProgression-free survivalBetter clinical outcomesDuration of responseOverall response rateTumor immune responseFurther clinical evaluationTumor cell-intrinsic mechanismsMAPK pathway inhibitionPatient-derived organoidsCell-intrinsic mechanismsOverall survival
2021
PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients
Liu H, Yousefi H, Mirian N, Lin M, Menard D, Gregory M, Aboian M, Boustani A, Chen M, Saperstein L, Pucar D, Kulon M, Liu C. PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients. IEEE Transactions On Radiation And Plasma Medical Sciences 2021, 6: 766-770. PMID: 37284026, PMCID: PMC10241407, DOI: 10.1109/trpms.2021.3131999.Peer-Reviewed Original Research
2004
Mycosis fungoides and the Sézary syndrome
Foss F. Mycosis fungoides and the Sézary syndrome. Current Opinion In Oncology 2004, 16: 421-428. PMID: 15314509, DOI: 10.1097/00001622-200409000-00002.Peer-Reviewed Original ResearchConceptsEarly-stage patientsSézary syndromeMycosis fungoidesTreatment paradigmPeptide-loaded dendritic cellsEvolution of immunotherapyUse of photopheresisClinical prognostic factorsNucleoside analogue therapyReceptor-directed therapyT cell responsesTreatment of patientsNon-Hodgkin lymphomaNovel treatment optionsFurther clinical evaluationNovel therapeutic approachesHistone deacetylase inhibitorsWorld Health OrganizationAnalogue therapySystemic therapyClinical stagingDendritic cellsPrognostic factorsSézary cellsClinical entity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply